Biocon-Mylan Share Sale: Bernstein Retains 'Underperform', Flags Three Key Risks Ahead

The brokerage retained its underperform rating and Rs 326 target price, saying the recent block deal does not materially change Biocon's long-term earnings outlook.

Jul 15, 2026 3

Biocon-Mylan Share Sale: Bernstein Retains 'Underperform', Flags Three Key Risks Ahead
The brokerage retained its underperform rating and Rs 326 target price, saying the recent block deal does not materially change Biocon's long-term earnings outlook.
Read More